430 related articles for article (PubMed ID: 24528105)
1. Endogenous interleukin (IL)-17A promotes pristane-induced systemic autoimmunity and lupus nephritis induced by pristane.
Summers SA; Odobasic D; Khouri MB; Steinmetz OM; Yang Y; Holdsworth SR; Kitching AR
Clin Exp Immunol; 2014 Jun; 176(3):341-50. PubMed ID: 24528105
[TBL] [Abstract][Full Text] [Related]
2. TLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy.
Summers SA; Hoi A; Steinmetz OM; O'Sullivan KM; Ooi JD; Odobasic D; Akira S; Kitching AR; Holdsworth SR
J Autoimmun; 2010 Dec; 35(4):291-8. PubMed ID: 20810248
[TBL] [Abstract][Full Text] [Related]
3. Nephritogenic autoantibodies but absence of nephritis in Il-12p35-deficient mice with pristane-induced lupus.
Calvani N; Satoh M; Croker BP; Reeves WH; Richards HB
Kidney Int; 2003 Sep; 64(3):897-905. PubMed ID: 12911539
[TBL] [Abstract][Full Text] [Related]
4. Suppression of Autoimmunity and Renal Disease in Pristane-Induced Lupus by Myeloperoxidase.
Odobasic D; Muljadi RC; O'Sullivan KM; Kettle AJ; Dickerhof N; Summers SA; Kitching AR; Holdsworth SR
Arthritis Rheumatol; 2015 Jul; 67(7):1868-80. PubMed ID: 25777776
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor 2 is required for autoantibody production and development of renal disease in pristane-induced lupus.
Urbonaviciute V; Starke C; Pirschel W; Pohle S; Frey S; Daniel C; Amann K; Schett G; Herrmann M; Voll RE
Arthritis Rheum; 2013 Jun; 65(6):1612-23. PubMed ID: 23450347
[TBL] [Abstract][Full Text] [Related]
6. Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus.
Mihaylova N; Bradyanova S; Chipinski P; Herbáth M; Chausheva S; Kyurkchiev D; Prechl J; Tchorbanov AI
Autoimmunity; 2017 Jun; 50(4):257-268. PubMed ID: 28300427
[TBL] [Abstract][Full Text] [Related]
7. IL-17C/IL-17 Receptor E Signaling in CD4
Krohn S; Nies JF; Kapffer S; Schmidt T; Riedel JH; Kaffke A; Peters A; Borchers A; Steinmetz OM; Krebs CF; Turner JE; Brix SR; Paust HJ; Stahl RAK; Panzer U
J Am Soc Nephrol; 2018 Apr; 29(4):1210-1222. PubMed ID: 29483158
[TBL] [Abstract][Full Text] [Related]
8. Targeted IgA Fc receptor I (FcαRI) therapy in the early intervention and treatment of pristane-induced lupus nephritis in mice.
Liu C; Kanamaru Y; Watanabe T; Tada N; Horikoshi S; Suzuki Y; Liu Z; Tomino Y
Clin Exp Immunol; 2015 Sep; 181(3):407-16. PubMed ID: 25907714
[TBL] [Abstract][Full Text] [Related]
9. Interferon-gamma is required for lupus nephritis in mice treated with the hydrocarbon oil pristane.
Richards HB; Satoh M; Jennette JC; Croker BP; Yoshida H; Reeves WH
Kidney Int; 2001 Dec; 60(6):2173-80. PubMed ID: 11737591
[TBL] [Abstract][Full Text] [Related]
10. Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis.
Savarese E; Steinberg C; Pawar RD; Reindl W; Akira S; Anders HJ; Krug A
Arthritis Rheum; 2008 Apr; 58(4):1107-15. PubMed ID: 18383384
[TBL] [Abstract][Full Text] [Related]
11. Modulation of the immune response in pristane-induced lupus by expression of activation and inhibitory Fc receptors.
Clynes R; Calvani N; Croker BP; Richards HB
Clin Exp Immunol; 2005 Aug; 141(2):230-7. PubMed ID: 15996187
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-17RA Promotes Humoral Responses and Glomerular Injury in Experimental Rapidly Progressive Glomerulonephritis.
Ghali JR; O'Sullivan KM; Eggenhuizen PJ; Holdsworth SR; Kitching AR
Nephron; 2017; 135(3):207-223. PubMed ID: 27941331
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus.
Richards HB; Satoh M; Shaw M; Libert C; Poli V; Reeves WH
J Exp Med; 1998 Sep; 188(5):985-90. PubMed ID: 9730900
[TBL] [Abstract][Full Text] [Related]
14. IL-2/anti-IL-2 complexes ameliorate lupus nephritis by expansion of CD4
Yan JJ; Lee JG; Jang JY; Koo TY; Ahn C; Yang J
Kidney Int; 2017 Mar; 91(3):603-615. PubMed ID: 27914701
[TBL] [Abstract][Full Text] [Related]
15. The Systemic Activation of Programmed Death 1-PD-L1 Axis Protects Systemic Lupus Erythematosus Model from Nephritis.
Liao W; Zheng H; Wu S; Zhang Y; Wang W; Zhang Z; Zhou C; Wu H; Min J
Am J Nephrol; 2017; 46(5):371-379. PubMed ID: 29069649
[TBL] [Abstract][Full Text] [Related]
16. Function of the Th17/interleukin-17A immune response in murine lupus nephritis.
Schmidt T; Paust HJ; Krebs CF; Turner JE; Kaffke A; Bennstein SB; Koyro T; Peters A; Velden J; Hünemörder S; Haag F; Steinmetz OM; Mittrücker HW; Stahl RA; Panzer U
Arthritis Rheumatol; 2015 Feb; 67(2):475-87. PubMed ID: 25385550
[TBL] [Abstract][Full Text] [Related]
17. Disparate T cell requirements of two subsets of lupus-specific autoantibodies in pristane-treated mice.
Richards HB; Satoh M; Jennette JC; Okano T; Kanwar YS; Reeves WH
Clin Exp Immunol; 1999 Mar; 115(3):547-53. PubMed ID: 10193432
[TBL] [Abstract][Full Text] [Related]
18. IL-12 deficiency in MRL-Fas(lpr) mice delays nephritis and intrarenal IFN-gamma expression, and diminishes systemic pathology.
Kikawada E; Lenda DM; Kelley VR
J Immunol; 2003 Apr; 170(7):3915-25. PubMed ID: 12646661
[TBL] [Abstract][Full Text] [Related]
19. Anti-complement factor H (CFH) autoantibodies could delay pristane-induced lupus nephritis.
Li LL; Luan ZQ; Tan Y; Wang H; Yu XJ; Qu Z; Yu F; Chen M
Immunol Res; 2023 Dec; 71(6):849-859. PubMed ID: 37322353
[TBL] [Abstract][Full Text] [Related]
20. Retinoic Acid Exerts Disease Stage-Dependent Effects on Pristane-Induced Lupus.
Abdelhamid L; Cabana-Puig X; Swartwout B; Lee J; Li S; Sun S; Li Y; Ross AC; Cecere TE; LeRoith T; Werre SR; Wang H; Reilly CM; Luo XM
Front Immunol; 2020; 11():408. PubMed ID: 32265909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
